At Rigel Pharmaceuticals, our purpose is to discover, develop and provide novel small molecule drugs.
In particular, we are focused on hematologic disorders, cancer and rare immune diseases. We see great opportunity to help patients who have diseases where few or no approved treatment options exist.
The company’s first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets*, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ITP is a rare autoimmune disease where the body’s own immune system attacks and destroys platelets in the blood.
Fostamatinib is currently being studied in a Phase 3 open-label extension study (NCT04138927) for the treatment of warm antibody autoimmune hemolytic anemia (wAIHA), a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with COVID-19, and an NIH/NHLBI-sponsored Phase 3 clinical trial (NCT04924660) for the treatment of COVID-19 in hospitalized patients.
Rigel’s portfolio also includes olutasidenib, an investigational, oral, small molecule inhibitor of mutated IDH1 currently being reviewed by the FDA for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
Our other clinical programs include an interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program. Rigel is collaborating with Eli Lilly to develop Rigel’s RIPK1 inhibitors in immunological and neurodegenerative diseases.
In addition, Rigel has an extensive portfolio of investigational agents being developed with our other partners. These products are focused on the inhibition of select signaling pathways, including Axl tyrosine kinase (AXL) and murine double minute 2 (MDM2). Through strategic partnerships and collaborations, we are able to take advantage of additional experience and resources, while benefiting from the potential success of these future products, both through milestone payments and royalties.
* Please see the TAVALISSE full prescribing information